Fluoroestradiol F-18
| Clinical data | |
|---|---|
| Trade names | Cerianna |
| Other names | [18F]16α-Fluoroestradiol; [18F]16α-Fluoroestra-1,3,5(10)-triene-3,17β-diol |
| License data | |
| Routes of administration | Intravenous injection |
| Drug class | Estrogen; Diagnostic radiopharmaceutical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Liver |
| Excretion | Gallbladder and kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H23[18F]O2 |
| Molar mass | 289.37 |
| 3D model (JSmol) | |
| |
| |
Fluoroestradiol F-18, also known as [18F]16α-fluoroestradiol and sold under the brand name Cerianna, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging. It is an analog of estrogen and is used to detect estrogen receptor-positive breast cancer lesions.